Issues regarding Pill Penalty caused by the Inflation Reduction Act (IRA) P.L. No: 117-169, drug pricing, and efforts to create a Neuroscience Center of Excellence at FDA. PBM Issues, including H.R./S._Modernizing and Ensuring PBM Accountability Act.
2025 · 3rd Quarter (July 1 - Sep 30)
LUNDBECK PHARMACEUTICALS LLC
Filed by CAPITOL COUNSEL LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 21, 2025
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL COUNSEL LLC
- Filing UUID
- cf5001ca-674a-4d1d-9faf-620627db0f28
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues regarding the Inflation Reduction Act (IRA) P.L. No: 117-169, drug pricing, and efforts to create a Neuroscience Center of Excellence at FDA. PBM Issues, including H.R./S._ Modernizing and Ensuring PBM Accountability Act and H.R./S._Lower Costs, More Transparency Act. Issues regarding effective solutions for improving clinical care in long-term care settings and other solutions aimed at improving the diagnosis and management of neuropsychiatric symptoms (NPS) in dementia. Orphan Drug Provisions included in HR.1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21.
Literal federal measure citations: HR.1
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.